122860-33-7

Usage

Uses

1. Used in Pharmaceutical Synthesis:
1-Cbz-4-hydroxymethylpiperidine is used as an intermediate in the synthesis of benzoyloxyethylpiperidinylmethylamine, which are fluorescent antagonists for human 5-HT4 receptors. These antagonists play a significant role in the development of drugs targeting serotonin receptors, which are implicated in various neurological and psychiatric disorders.
2. Used in the Development of Potent Antagonists:
1-Cbz-4-hydroxymethylpiperidine is also utilized in the preparation of diaminobutane derivatives, which are potent Ca2+-Permeable AMPA receptor antagonists. AMPA receptors are involved in synaptic plasticity and excitatory neurotransmission, making them important targets for the treatment of conditions such as epilepsy, Alzheimer's disease, and other neurological disorders.

InChI:InChI=1/C14H19NO3/c16-10-12-6-8-15(9-7-12)14(17)18-11-13-4-2-1-3-5-13/h1-5,12,16H,6-11H2

Upstream product

• 160809-38-1 1-benzyl 4-ethyl piperidine-1,4-dicarboxylate 
• 10314-98-4 1-benzyloxycarbonylpiperidine-4-carboxylic acid 
• 1126-09-6 4-carbethoxypiperidine 
• 501-53-1 benzyl chloroformate 
• 6457-49-4 4-piperidinemethanol 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 31139-36-3 dibenzyl dicarbonate 
• 1885-14-9 phenyl chloroformate 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 498-94-2 isonipecotic acid 

Downstream Products

• 159275-17-9 benzyl 4-(bromomethyl)tetrahydro-1-(2H)-pyridinecarboxylate 
• 149897-41-6 1-benzyloxycarbonyl-4-piperidylmethyl iodide 
• 167843-51-8 benzyl 4-((2-ethoxy-2-oxoethoxy)methyl)piperidine-1-carboxylate 
• 138163-08-3 N-(benzyloxycarbonyl)piperidine-4-carboxaldehyde 
• 247132-98-5 benzyl 4-(2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinolin-7-yloxymethyl)piperidin-1-carboxylate 
• 159275-16-8 1-(benzyloxycarbonyl)piperidin-4-ylmethyl methanesulfonate 
• 160586-68-5 4-(toluene-4-sulfonyloxymethyl)piperidine-1-carboxylic acid benzyl ester 
• 1214285-49-0 butyl 4-[(2S)-2-(([4-((1-[(benzyloxy)carbonyl]piperidin-4-yl)-methoxy)-6-phenylpyridin-2-yl]carbonyl)amino)-5-tert-butoxy-5-oxopentanoyl]piperazine-1-carboxylate 
• 1355455-38-7 benzyl 4-((acetylsulfanyl)methyl)piperidine-1-carboxylate 
• 1211587-42-6 benzyl 4-[(chlorosulfonyl)methyl]piperidine-1-carboxylate 
• 178261-41-1 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine] 
• 167484-18-6 benzyl spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 184289-84-7 benzyl 1-(methylsulfonyl)spiro[indoline-3,4’-piperidine]-1‘-carboxylate 
• 180465-67-2 C₂₃H₂₉N₃O₄S 

Relevant academic research and scientific papers

A facile synthesis of the spiroindoline-based growth hormone secretagogue, MK-677

A facile and improved route for the synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 was described. The key step adopted the Fischer indole/reduction strategy. The preparation of the key intermediates N-protected piperidine carboxaldehyde 5 and the N-Boc-O-benzyl-d-serine (2) are also optimized.

Design and Synthesis of Novel N-(2-aminophenyl)benzamide Derivatives as Histone Deacetylase Inhibitors and Their Antitumor Activity Study

Histone deacetylases (HDACs) are promising therapeutic targets for cancer therapy because inhibition of HDACs triggers growth arrest or apoptosis of tumor cells. In the present study, a new series of fluorinated N-(2-aminophenyl)benzamide derivatives were synthesized to investigate potential inhibition of HDACs and associated anticancer activity. Among the synthesized derivatives, compound 24a showed potent inhibitory activity of HDACs and higher antitumor efficacy in human cancer cell lines (HCT-116, MCF-7, and A549) compared with SAHA. Moreover, animal studies demonstrated that compound 24a showed potent in vivo antitumor efficacy in an HCT-116 colon cancer xenograft mouse model.

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyrimidine-based protein kinase D inhibitors

The multiple roles of protein kinase D (PKD) in various cancer hallmarks have been repeatedly reported. Therefore, the search for novel PKD inhibitors and their evaluation as antitumor agents has gained considerable attention. In this work, novel pyrazolo[3,4-d]pyrimidine based pan-PKD inhibitors with structural variety at position 1 were synthesized and evaluated for biological activity. Starting from 3-IN-PP1, a known PKD inhibitor with IC50 values in the range of 94–108 nM, compound 17m was identified with an improved biochemical inhibitory activity against PKD (IC50 = 17–35 nM). Subsequent cellular assays demonstrated that 3-IN-PP1 and 17m inhibited PKD-dependent cortactin phosphorylation. Furthermore, 3-IN-PP1 displayed potent anti-proliferative activity against PANC-1 cells. Finally, a screening against different cancer cell lines demonstrated that 3-IN-PP1 is a potent and versatile antitumoral agent.

THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER

The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and withou

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

Nickel-Catalyzed C-Alkylation of Nitroalkanes with Unactivated Alkyl Iodides

Enabled by nickel catalysis, a mild and general catalytic method for C-alkylation of nitroalkanes with unactivated alkyl iodides is described. Compatible with primary, secondary, and tertiary alkyl iodides; and tolerant of a wide range of functional groups, this method allows rapid access to diverse nitroalkanes.

Highly regioselective gold-catalyzed formal hydration of propargylic: Gem -difluorides

Herein, we report a highly regioselective gold-catalyzed formal hydration of propargylic gem-difluorides. Not only does this transformation provide access to versatile fluorinated building blocks that were difficult or hardly possible to access beforehand, but it also represents a rare case of a highly regioselective gold-catalyzed hydroalkoxylation of internal alkynes and puts forward the utility of the difluoromethylene unit as a directing group in catalysis.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Compounds of formula I, defined herein, act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for treating broncho-obstructive and inflammatory diseases.

INHIBITORS OF CYTOMEGALOVIRUS

Compounds of Formula (I) wherein R1, R2, R3A, R3B, Y, Z1 and Z2 are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.

A library of conformationally restricted saturated heterocyclic sulfonyl chlorides

An approach to the synthesis of conformationally restricted saturated heterocyclic sulfonyl chlorides is described. Being guided by the principle of diversity-oriented conformational restriction, a mini-library of saturated heterocyclic sulfonyl chlorides